As usual, this year’s American Diabetes Association Scientific Sessions didn’t place much emphasis on a healthy lifestyle. There was food everywhere, and trust me, we’re not talking fruits & veggies. But there was a great deal of research presented on diabetes medications and devices.
One of the best examples I’ve come across in the “regulation vs. right to choose” debate related to diabetes technology is the We Are Not Waiting movement within the diabetes space.
There is no doubt that CGM can improve the quality of life and blood sugar control for just about everyone with diabetes. But which system is best for you?
IDS Clinicians Offer Different Perspectives on the Medtronic 670G after 10 days of use. Read what they have to say...
Integrated Diabetes Services answers your questions about living with type 1 diabetes, offers tips an tricks to managing weight, blood sugar and overall health. Todays question deals with carbs - how many is just enough...
Diabetes educator, Gary Scheiner gives his in-depth review of the newly approved Abbott Freestyle Libre CGM continuous glucose monitor.
The 670G represents an important step towards fully automating glucose control. However, it is important to put it in the proper context and set expectations at an appropriate level.
what happens when we eat with reckless abandon and blood glucose levels start to head in the wrong direction? Being the responsible individuals we are, we usually place the blame squarely where it belongs: on our medication.
Novo Nordisk’s new FiASP insulin (short for Faster insulin Aspart) has hit the market in various parts of the world, and is awaiting FDA clearance here in the US.
By avoiding the need to absorb through the fat layer below the skin, Afrezza starts working almost immediately, peaks in about 15 minutes, and in most cases, clears in about 2 hours. Now that’s rapid!